Edema Macular en Pacientes Diabeticos
To compare the effect between ranibizumabintravitrealvsranibizumabtriamcinolone and macular edema in diabetic patients treated at the Department of Ophthalmology at MiguelPérezCarreñoHospital in the period between July 2010 and July 2011. Method: This is a descriptive, prospective longitudinal perfo...
Saved in:
| Published: |
2013
|
|---|---|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10872/18136 |
| Tags: |
No Tags, Be the first to tag this record!
|
| Summary: | To compare the effect between ranibizumabintravitrealvsranibizumabtriamcinolone and macular edema in diabetic patients treated at the Department of Ophthalmology at MiguelPérezCarreñoHospital in the period between July 2010 and July 2011. Method: This is a descriptive, prospective longitudinal performed in diabetic patients with macular edema who were injected in both eyes; in one eye applied intravitreal injection of ranibizumab 0.1ml (1.25mg) and in a second was placed 0.1 ml (1.25 mg) of ranibizumab combined with 0.2 ml (8 mg) of triamcinolone. Proceeded to perform successive controls at weeks 1, 4, 8 and 12 verifying better visual acuity and foveal thickness obtained by using the OCT. Also it was meant to determine several complications such as increased IOP and posterior subcapsular cataract among others. Results: 12 patients initially studied, 2 excluded due to macular ischemia and posterior subcapsular cataract, respectively, for a total of 10 patients who completed the study. In patients undergoing ranibizumab only, evidenced a mean initial BCVA of 0.54 (0.64) logMAR and at 12 weeks of 0.45. In patients undergoing ranibizumab and triamcinolone showed a mean initial BCVA of 0.68 logMAR and at 12 weeks of 0.69. In patients undergoing ranibizumab showed only half of initial GMC 449 ± 260 microns and 12 weeks of 329 ± 155 microns. In patients undergoing ranibizumab and triamcinolone showed a mean initial GMC 372 ± 141 microns and 12 weeks of 371 ± 220 microns. The variation of IOP showed no statistical differences between groups. Conclusions: Up to 12 weeks, intravitrealranibizumab treatment of patients with DME yielded better visual outcome than ranibizumab-triamcinolone group, although it was not associated with a significant decrease in CMT. No further beneficial effect of intravitreal triamcinolone could be demonstrated. Further clinical trials with longer follow-up are required to evaluate the long-term visual outcomes and complication profiles after primary treatment with such medications |
|---|